Epigenetic reprogramming in liver fibrosis and cancer
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Novel insights into the epigenetic control of chronic liver diseases are now emerging. Recent advances in our understanding of the critical roles of DNA methylation, histone modifications and ncRNA may now be exploited to improve management of fibrosis/cirrhosis and cancer. Furthermore, improved technologies for the detection of epigenetic markers from patients' blood and tissues will vastly improve diagnosis, treatment options and prognostic tracking. The aim of this review is to present recent findings from the field of liver epigenetics and to explore their potential for translation into therapeutics to prevent disease promoting epigenome reprogramming and reverse epigenetic changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · cited 1×
“Discovery of the three ten eleven translocation (TET1-3) enzymes, which catalyse progressive oxidation of the 5-meCpG mark, implies that DNA methylation is more dynamic than previously thought [10].”
Genome-scale DNA methylation maps of pluripotent and differentiated cells
Meissner, A., Mikkelsen, T. S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., Zhang, X., Bernstein, B. E., Nusbaum, C., Jaffe, D. B., et al. (2008) · Nature · doi:10.1038/nature07107 · Cited by 2,536
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
MicroRNAs 103 and 107 regulate insulin sensitivity
Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., Heim, M. H., & Stoffel, M. (2011) · Nature · doi:10.1038/nature10112 · Cited by 1,000
Microbiota Diurnal Rhythmicity Programs Host Transcriptome Oscillations
Thaiss, C. A., Levy, M., Korem, T., Dohnalová, L., Shapiro, H., Jaitin, D. A., David, E., Winter, D. R., Gury-BenAri, M., Tatirovsky, E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.003 · Cited by 870 · cited 1×
“has shown that the gutmicrobiota exhibits a diurnal rhythmicity that programs in a circadianmanner the liver transcriptome and its detoxification pattern [38].”
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776 · cited 1×
“However, more specific EZH2 inhibitors including EPZ005687 and EPZ011989 are now available and have proved very successful at killing lymphoma cells, these new drugs may show therapeutic promise in EZH2 high HCC patients [92,93].”
A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism
Feng, D., Liu, T., Sun, Z., Bugge, A., Mullican, S. E., Alenghat, T., Liu, X. S., & Lazar, M. A. (2011) · Science · doi:10.1126/science.1198125 · Cited by 701
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
MeCP2 Controls an Epigenetic Pathway That Promotes Myofibroblast Transdifferentiation and Fibrosis
Mann, J., Chu, D. C. K., Maxwell, A., Oakley, F., Zhu, N., Tsukamoto, H., & Mann, D. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.002 · Cited by 397 · cited 3×
“Significantly, HSC isolated from mice deficient in MeCP2 show attenuated levels of classical myofibroblasts markers such as α-smooth muscle actin (αSMA) or collagen 1 and are protected from carbon tetrachloride (CCl4) induced liver fibrosis [43].”
Self-citationHepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration
Sun, Z., Miller, R. A., Patel, R. T., Chen, J., Dhir, R., Wang, H., Zhang, D., Graham, M. J., Unterman, T. G., Shulman, G. I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2744 · Cited by 335 · cited 1×
“HDAC3 is an important circadian regulated epigenetic writer critical for hepatic triglyceride homoeostasis and when deleted in mice results in steatosis, inflammation and fibrosis [31,32].”
Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310284200 · Cited by 320
Multigenerational epigenetic adaptation of the hepatic wound-healing response
Zeybel, M., Hardy, T., Wong, Y. K., Mathers, J. C., Fox, C. R., Gackowska, A., Oakley, F., Burt, A. D., Wilson, C. L., Anstee, Q. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2893 · Cited by 279
Self-citationNon-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241 · cited 1×
“As the gut microbiota is dramatically modified in alcoholic and non-alcoholic liver diseases this new discovery has major implications for epigenetic control of oscillatory hepatic gene expression and liver function [39,40].”
Hardy, T., Zeybel, M., Day, C. P., Dipper, C., Masson, S., McPherson, S., Henderson, E., Tiniakos, D., White, S., French, J., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311526 · Cited by 216
Self-citationBRD4 is a novel therapeutic target for liver fibrosis
Ding, N., Hah, N., Yu, R. T., Sherman, M. H., Benner, C., Leblanc, M., He, M., Liddle, C., Downes, M., & Evans, R. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522163112 · Cited by 211 · cited 1×
“described BRD4 binding at the enhancers of fibrogenic genes and presented data suggesting that the BRD4 inhibitor JQ1 may be able to suppress or even reverse fibrosis in vivo [65].”
Zeybel, M., Hardy, T., Robinson, S. M., Fox, C., Anstee, Q. M., Ness, T., Masson, S., Mathers, J. C., French, J., White, S., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0056-6 · Cited by 180
NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma
Wilson, C. L., Jurk, D., Fullard, N., Banks, P., Page, A., Luli, S., Elsharkawy, A. M., Gieling, R. G., Chakraborty, J. B., Fox, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms7818 · Cited by 171 · cited 1×
“More recentlywe showed that aged mice lacking p50 succumb to spontaneous fibrosis [60].”
Self-citationElsharkawy, A. M., Oakley, F., Lin, F., Packham, G., Mann, D. A., & Mann, J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.025 · Cited by 160 · cited 1×
“Our laboratory described a role for HDAC1 as an epigenetic co-repressor of NF-κB p50:p50 mediated dampening of inflammatory andfibrogenic gene transcription inHSC [59].”
Self-citation
Cited by
LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer
Wang, Y., Lu, J.-H., Wu, Q.-N., Jin, Y., Wang, D.-S., Chen, Y.-X., Liu, J., Luo, X.-J., Meng, Q., Pu, H.-Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1105-0 · Cited by 507
Epigenetics in hepatocellular carcinoma
Nagaraju, G. P., Dariya, B., Kasa, P., Peela, S., & El-Rayes, B. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.017 · Cited by 339
Pathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 285
Hamdane, N., Jühling, F., Crouchet, E., El Saghire, H., Thumann, C., Oudot, M. A., Bandiera, S., Saviano, A., Ponsolles, C., Roca Suarez, A. A., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.038 · Cited by 275
Zhang, H., Ma, Y., Cheng, X., Wu, D., Huang, X., Chen, B., Ren, Y., Jiang, W., Tang, X., Bai, T., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1206 · Cited by 65
Metadata
- Authors
- Wilson, C. L., Mann, D. A., & Borthwick, L. A.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 121
- Pages
- 124-132
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2766602609
- Cited by
- 96
- References
- 21
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.